CN107660202B - 水溶性前药 - Google Patents

水溶性前药 Download PDF

Info

Publication number
CN107660202B
CN107660202B CN201680030052.0A CN201680030052A CN107660202B CN 107660202 B CN107660202 B CN 107660202B CN 201680030052 A CN201680030052 A CN 201680030052A CN 107660202 B CN107660202 B CN 107660202B
Authority
CN
China
Prior art keywords
group
bis
groups
optionally substituted
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680030052.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107660202A (zh
Inventor
坂仁志
上冈正儿
泽山裕介
李嘉强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Sumitomo Pharma Oncology Inc
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Oncology Inc
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Oncology Inc, Boston Biomedical Inc filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of CN107660202A publication Critical patent/CN107660202A/zh
Application granted granted Critical
Publication of CN107660202B publication Critical patent/CN107660202B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680030052.0A 2015-03-27 2016-03-25 水溶性前药 Expired - Fee Related CN107660202B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139077P 2015-03-27 2015-03-27
US62/139,077 2015-03-27
PCT/IB2016/051706 WO2016157052A1 (en) 2015-03-27 2016-03-25 Water-soluble prodrugs

Publications (2)

Publication Number Publication Date
CN107660202A CN107660202A (zh) 2018-02-02
CN107660202B true CN107660202B (zh) 2021-12-24

Family

ID=55650622

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680030052.0A Expired - Fee Related CN107660202B (zh) 2015-03-27 2016-03-25 水溶性前药

Country Status (7)

Country Link
US (3) US10183925B2 (enExample)
EP (1) EP3274346A1 (enExample)
JP (3) JP6630364B2 (enExample)
CN (1) CN107660202B (enExample)
CA (1) CA2980845A1 (enExample)
TW (1) TWI710555B (enExample)
WO (1) WO2016157052A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016157052A1 (en) 2015-03-27 2016-10-06 Boston Biomedical, Inc. Water-soluble prodrugs
JP6936214B2 (ja) 2016-03-25 2021-09-15 大日本住友製薬株式会社 ２−アルキルカルボニルナフト［２，３−ｂ］フラン−４，９−ジオンの関連物質の製造方法、及びその関連物質
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
US20200207782A1 (en) * 2017-09-22 2020-07-02 Sumitomo Dainippon Pharma Co., Ltd Chemically activated water-soluble prodrug
JPWO2021039616A1 (enExample) * 2019-08-23 2021-03-04
FR3112145A1 (fr) * 2020-07-03 2022-01-07 Nanotracks Diagnostics Derives uree de macrolides polyeniques, composes chimiques particuliers susceptibles d’etre utilises pour obtenir ces derives uree, compositions les contenant et utilisations
WO2022003181A1 (fr) * 2020-07-03 2022-01-06 Nanotracks Diagnostics Derivés urée de l'amphotéricine amb, compositions les contenant et leurs utilisations, dérivés isocyanate d'alkyle omega-aminés et leur utilisation pour obtenir lesdits dérivés urée
CN112194598B (zh) * 2020-10-15 2021-12-21 郑州猫眼农业科技有限公司 3-(叔丁氧基羰基-r氧基羰基甲基-氨基)-丙酸酯的制备方法
EP4431491A4 (en) * 2021-11-08 2025-03-05 Asahi Kasei Kabushiki Kaisha CARBONYL COMPOUND, METHOD FOR PRODUCING A CARBONYL COMPOUND, METHOD FOR PRODUCING AN ISOCYANATE COMPOUND AND ISOCYANATE COMPOSITION
CN118302407A (zh) * 2021-11-08 2024-07-05 旭化成株式会社 羰基化合物、羰基化合物的制造方法、异氰酸酯化合物的制造方法以及异氰酸酯组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402993A (zh) * 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯
CN104080449A (zh) * 2012-02-17 2014-10-01 舟山海中洲新生药业有限公司 4，9-二羟基-萘并[2，3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160949T1 (hr) 2007-09-10 2016-10-07 Boston Biomedical, Inc. Novi sastavi i metode za liječenje karcinoma
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
WO2016157052A1 (en) * 2015-03-27 2016-10-06 Boston Biomedical, Inc. Water-soluble prodrugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402993A (zh) * 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯
CN104080449A (zh) * 2012-02-17 2014-10-01 舟山海中洲新生药业有限公司 4，9-二羟基-萘并[2，3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法

Also Published As

Publication number Publication date
US10183925B2 (en) 2019-01-22
JP2020055854A (ja) 2020-04-09
JP6885999B2 (ja) 2021-06-16
TW201639824A (zh) 2016-11-16
US20190084955A1 (en) 2019-03-21
HK1243079A1 (zh) 2018-07-06
JP2021120401A (ja) 2021-08-19
JP2018509441A (ja) 2018-04-05
US11414394B2 (en) 2022-08-16
EP3274346A1 (en) 2018-01-31
TWI710555B (zh) 2020-11-21
CA2980845A1 (en) 2016-10-06
WO2016157052A1 (en) 2016-10-06
CN107660202A (zh) 2018-02-02
US20180111914A1 (en) 2018-04-26
JP6630364B2 (ja) 2020-01-15
US10800752B2 (en) 2020-10-13
US20200392098A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
CN107660202B (zh) 水溶性前药
AU2023202592B2 (en) Modulators of the integrated stress pathway
CN109415360B (zh) 用于抑制shp2活性的化合物和组合物
CN105899491B (zh) 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物
CN109863140B (zh) 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺
ES2944573T3 (es) Antagonistas de TLR7/8 y usos de los mismos
ES2588680T3 (es) Compuestos de tiazolopirimidina
EP3713926B1 (en) 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
CN114450287A (zh) Shp2磷酸酶抑制剂及其制备和使用方法
CN105899493A (zh) 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
EP3713923B1 (en) 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
JP2022519924A (ja) 補体媒介性障害の治療のための医薬化合物
WO2019096911A1 (en) Macrocyclic indole derivatives
CN116323590A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
EA028059B1 (ru) Твердые формы n-((s)-2,3-дигидроксипропил)-3-(2-фтор-4-йодфениламино)изоникотинамида
HK1243079B (zh) 水溶性前药
WO2022171018A1 (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN118434726A (zh) 具有二环性骨架的1h-吡唑-3-胺衍生物
AU2020284308A1 (en) Asparagine endopeptidase (AEP) inhibitors, compositions, and uses related thereto
HK40074209A (en) Shp2 phosphatase inhibitors and methods of making and using the same
HK40068645B (zh) 天冬酰胺内肽酶(aep)抑制剂、与其相关的组合物和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1243079

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: Sumitomo pharmaceutical oncology Co.,Ltd.

Applicant after: Dainippon Sumitomo Pharma Co.,Ltd.

Address before: Massachusetts, USA

Applicant before: BOSTON BIOMEDICAL Inc.

Applicant before: Dainippon Sumitomo Pharma Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Massachusetts

Patentee after: Sumitomo pharmaceutical oncology Co.,Ltd.

Patentee after: SUMITOMO PHARMACEUTICALS CO.,LTD.

Address before: Massachusetts

Patentee before: Sumitomo pharmaceutical oncology Co.,Ltd.

Patentee before: Dainippon Sumitomo Pharma Co.,Ltd.

CP01 Change in the name or title of a patent holder
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20211224